Capricor Therapeutics develops cell- and exosome-based therapies for rare neuromuscular and cardiac diseases. Its lead program, deramiocel (CAP-1002), uses cardiosphere-derived cells aimed at Duchenne muscular dystrophy and related cardiomyopathy. The company focuses on regenerative approaches rather than traditional small-molecule drugs, targeting patients with limited treatment options.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -25.9 | — |
| Q3 2025 | 0 | — | -24.6 | — |
| Q4 2025 | 0 | — | -30.2 | — |
| Q1 2026 | 0 | — | -33.9 | — |
| Q2 2026 | 0 | — | -40.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Berto Acquisition Corp. II (GUAC), Chemung Financial Corporation (CHMG), The First Bancorp, Inc. (FNLC), Obook Holdings Inc. (OWLS), Citizens Financial Services, Inc. (CZFS), TRex Bio, Inc. (TRXB)